Synthetic opioid production in Europe with Paul Griffiths

Addiction Audio

In this episode, Dr Elle Wadsworth talks to Paul Griffiths about synthetic drug production in Europe including the differences between lab-made substances and diverted medical drugs. They discuss organised crime and its impact on cocaine production, drug availability and the potential for drug contamination. They also cover fentanyl and the potential for a heroin drought resulting from changes in opium production in Afghanistan.

Paul talks about the complexities of European drug markets explaining how they commonly respond to changes in both supply and demand. Elle and Paul then discuss how researchers can monitor drug trends through wastewater analysis and other methods.

“These are often very small labs, but because of the potency of these drugs, it means very small production runs can have quite a big impact on local drug consumption patterns and mortality and morbidity. So we saw a few years ago, ten or fifteen years, one lab in central Europe we had a very brief outbreak of deaths in about three countries all related to a very very small, a kitchen lab it was actually in someone’s kitchen but it had an impact.”

Paul Griffiths is the scientific director for the EMCDDA – the European Monitoring Centre for Drugs and Drug Addiction

Original article: Opioid problems are changing in Europe with worrying signals that synthetic opioids may play a more significant role in the future by Paul Griffiths and colleagues. Published in Addiction (2024)

The opinions expressed in this post reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.

The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information.

---

Hosted on Acast. See acast.com/privacy for more information.